代谢综合征与前列腺癌发病风险的相关性分析  

Metabolic syndrome and the risk of prostate cancer

作　　者：侯文杰[1] 浦金贤[1] 丁翔[1] 陆勇[1] 平季根[1] 侯建全[1] 席启林[1] 赵晓俊[1] 

机构地区：[1]苏州大学附属第一医院泌尿外科,215000

出　　处：《现代泌尿生殖肿瘤杂志》2010年第6期332-334,340,共4页Journal of Contemporary Urologic and Reproductive Oncology

摘　　要：目的分析前列腺癌患者中代谢综合征(metabolic syndrome,MS)发病情况并探讨MS与前列腺癌发病风险的相关性。方法回顾性分析2006年11月1日至2010年9月1日我院收治的203例前列腺癌患者的临床资料,包括患者年龄、身高、体重、前列腺体积、前列腺特异性抗原(PSA)水平、血压、空腹血糖、甘油三酯及总胆固醇水平、病理结果、Gleason评分等指标,其中171例(84%)采用雄激素阻断治疗(androgen deprivation therapy,ADT),观察患者随访治疗期间血压、空腹血糖、甘油三酯及总胆固醇水平。结果在初次确诊的203例前列腺癌患者中,166例(81.77%)患MS,其中糖尿病患者44例(26.50%),高血糖症患者29例(17.68%),高血压患者114例(68.67%),高胆固醇或高甘油三脂患者84例(50.60%)。非MS前列腺癌患者37例(18.22%)。MS前列腺癌患者的体重指数(BMI)、血糖、前列腺体积及PSA水平与非MS前列腺癌患者比较差异具有统计学意义(均P<0.05),年龄及Gleason评分在两组前列腺癌患者间差异无统计学意义。随访治疗期间153例(90.05%)患MS,其中糖尿病患者49例(32.02%),高血糖症患者38例(24.8%),高血压患者105例(68.62%),高胆固醇或高甘油三脂患者86例(56.22%)。非MS患者18例(10.53%)。MS发生几率较治疗前明显升高。结论本研究发现大多数前列腺癌患者同时罹患MS,MS前列腺癌患者较非MS前列腺癌患者的BMI、血糖、前列腺体积升高,PSA水平降低,可能影响前列腺癌早期诊断和治疗,增加漏诊率。接受长期ADT治疗的前列腺癌患者中MS发生率明显增加,大大增加了其患心血管疾病的危险度。Objective To investigated the relationship between metabolic syndrome（MS） and the risk of prostate cancer. Methods A retrospective study was conducted in 203 men with incident histological confirmed prostate cancer between 2006.11.1 and 2010.9.1, and we reviewed clinb cal datas including follow-up treatment period, specifically the components of the MS, to evaluate the prevalence of MS at the initial diagnosis of prostate cancer and following-up treatment. Results Among the 203 subjects with prostate cancer, 166 cases（81. 770//00） had MS and 37 cases（18.22o/00） without MS. 44 cases（26.50%） suffered with diabetes mellitus, 114 cases（68.67%） suffered with hypertension meanwhile 84 cases（50.60 %） was hypercholesterolemia or hypertriglyceridemia. BMI, blood glucose, prostate volume and PSA are statistically significantly different in patients with MS from patients without MS. 153 cases were diagnosis with MS in follow-up treatment and in which 49 eases（32. 02%） suffered with diabetes mellitus, 105 cases（68. 62%） suffered with hypertension meanwhile 86 cases（56.22 %） was hypercholesterolemia or hypertriglyeeridemia. Incidence of MS in follow-up treatment was significantly higher. Conclusions We conclude that the prevalence of the MS is higher in subjects with prostate cancer, compared with patients without MS, prostate cancer patients with MS have higher BMI, blood glucose, prostate volume and lower PSA. These charac- ters will reduce the biospy rate and impact on the early diagnosis and treatment of prostate cancer. Patients undertake ADT have higher risk in myocardial disease.

关 键 词：前列腺癌 代谢综合征 体重指数 雄激素阻断治疗 

分 类 号：R737.25[医药卫生—肿瘤]